Beranda › Kanker Paru Non-Sel Kecil › Minnesota › Duluth
Uji klinis Kanker Paru Non-Sel Kecil di Duluth, MN
13 studi untuk Kanker Paru Non-Sel Kecil mencari peserta di lokasi sekitar Duluth (dalam radius sekitar 30 mil). Buka studi untuk melihat kriteria peserta dan cara menghubungi tim studi.
Teks studi resmi (Bahasa Inggris)
Merekrut peserta untuk studi di sini? Tampilkan di bagian atas halaman ini — $99 selama 30 hari →
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Menerima pesertaFase 3
- Essentia Health Cancer Center, Duluth
A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After Treatment
Menerima pesertaFase 2
- Essentia Health Cancer Center, Duluth
- Essentia Health Saint Mary's Medical Center, Duluth
- Miller-Dwan Hospital, Duluth
- dan 1 lainnya
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
Menerima pesertaFase 3
- Essentia Health Cancer Center, Duluth
Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations
Menerima pesertaFase 1/2
- St. Luke'S /ID# 273344, Duluth
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
Menerima pesertaFase 3
- Research Site, Duluth
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
Menerima pesertaFase 3
- Clinical Study Sites, Duluth
Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
Menerima pesertaFase 3
- Miller-Dwan Hospital, Duluth
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
Menerima pesertaFase 2
- Essentia Health Cancer Center, Duluth
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
Menerima pesertaFase 2
- Essentia Health Cancer Center, Duluth
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
Menerima pesertaFase 2
- Essentia Health Cancer Center, Duluth
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
Menerima pesertaFase 2/3
- Essentia Health Cancer Center, Duluth
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
Menerima pesertaStudi observasional
- Essentia Health Cancer Center, Duluth
- Saint Luke's Hospital of Duluth, Duluth
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Menerima pesertaStudi observasional
- Massive Bio SYNERGY-AI site, Duluth
Uji klinis Kanker Paru Non-Sel Kecil di kota lain
- Houston, TX145 studi
- New York City, NY120 studi
- Arlington, VA104 studi
- Nashville, TN97 studi
- Boston, MA90 studi
- Los Angeles, CA87 studi
- St. Louis, MO73 studi
- Chicago, IL61 studi
- Baltimore, MD60 studi
- San Antonio, TX59 studi
- Columbus, OH56 studi
- Washington, DC55 studi
Studi lain di Duluth
- Kanker Paru11 studi
- Kanker Prostat7 studi
- Kanker Payudara7 studi
- Kanker Kolon6 studi
- Kanker Kandung Kemih6 studi
- Leukemia Mieloid Akut6 studi
- Kanker Endometrium5 studi
- Kanker Lambung5 studi
- Kanker Rektum5 studi
- Kanker Esofagus5 studi
- Kanker Laring5 studi
- Melanoma5 studi
Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.